Insmed Incorporated (NASDAQ:INSM) Shares Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC increased its position in Insmed Incorporated (NASDAQ:INSM) by 13.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,861 shares of the biopharmaceutical company’s stock after acquiring an additional 464 shares during the quarter. Sanctuary Advisors LLC’s holdings in Insmed were worth $295,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Jennison Associates LLC lifted its stake in shares of Insmed by 0.6% during the 4th quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock worth $53,424,000 after purchasing an additional 4,560 shares during the period. Capital CS Group LLC acquired a new stake in Insmed in the 4th quarter valued at $586,000. Orion Portfolio Solutions LLC increased its holdings in Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock valued at $2,050,000 after purchasing an additional 9,170 shares in the last quarter. Ally Bridge Group NY LLC increased its holdings in Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock valued at $11,011,000 after purchasing an additional 21,833 shares in the last quarter. Finally, TimesSquare Capital Management LLC acquired a new stake in Insmed in the 3rd quarter valued at $35,322,000.

Insider Buying and Selling

In related news, CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.72, for a total transaction of $67,925.52. Following the completion of the sale, the chief financial officer now owns 118,863 shares of the company’s stock, valued at approximately $7,573,950.36. The trade was a 0.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO William Lewis sold 18,750 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at $27,079,091.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 532,207 shares of company stock worth $41,400,465 over the last ninety days. Company insiders own 4.60% of the company’s stock.

Insmed Price Performance

Shares of INSM stock opened at $77.21 on Wednesday. The firm’s 50 day moving average price is $75.32 and its two-hundred day moving average price is $73.81. The stock has a market cap of $13.97 billion, a PE ratio of -13.81 and a beta of 1.11. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. As a group, analysts forecast that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

INSM has been the subject of several recent analyst reports. Stifel Nicolaus lowered their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Wells Fargo & Company raised their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a report on Wednesday, February 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Truist Financial lifted their price target on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a report on Friday, February 21st. Finally, Royal Bank of Canada assumed coverage on shares of Insmed in a research note on Tuesday, February 25th. They set an “outperform” rating and a $100.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and an average target price of $91.60.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.